NeuroSense Therapeutics has released early biomarker results from a small Phase 2 trial testing PrimeC — an oral drug originally developed for ALS — in Alzheimer's disease. The findings show changes in key Alzheimer's biomarkers, including tau and amyloid proteins, and mirror biological shifts previously seen in ALS patients. This suggests different neurodegenerative diseases may share common biological pathways, supporting a multi-target treatment approach rather than the traditional single-target drug strategy. While the trial involved only eight participants and does not yet prove clinical benefit, the safety profile was clean and the biological signals are encouraging for researchers pursuing broader neurodegeneration strategies.
